Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Michael P Dube, MD

    TitleProfessor of Medicine (Clinical Scholar)
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressGNH 5P2 349
    Health Sciences Campus
    Los Angeles California 90089-9316
    Phone+1 323 343 8288
    Emailmdube@usc.edu
    vCardDownload vCard
      Other Positions
      TitleAssociate Medical Director of The Rand Schrader Ai Ds Clinic


      Collapse Overview 
      Collapse Overview
      Dr. Dubé is an attending physician at the Los Angeles County-USC Medical Center in Los Angeles. He is the Associate Director of the 5P21 Rand Schrader Health and Research Center at LA County-USC Medical Center. Dr. Dubé is also a Professor of Medicine at USC's Keck School of Medicine.

      Dr. Dubé earned his medical degree from Boston University School of Medicine. He then went on to complete his internship, residency and fellowship at LAC+USC Medical Center, specializing in Infectious Diseases.


      Collapse Biography 
      Collapse Clinical Trials

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Lake JE, Stanley TL, Apovian CM, Bhasin S, Brown TT, Capeau J, Currier JS, Dube M, Falutz J, Grinspoon SK, Guaraldi G, Martinez E, McComsey GA, Sattler FR, Erlandson KM. Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection. Clin Infect Dis. 2017 May 15; 64(10):1422-1429. PMID: 28329372.
        View in: PubMed
      2. Kelesidis T, Jackson N, McComsey GA, Wang X, Elashoff D, Dube M, Brown TT, Yang OO, Stein JH, Currier JS. Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS. 2016 Nov 13; 30(17):2625-2633. PMID: 27603288.
        View in: PubMed
      3. Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dube M, Yang OO, McComsey GA, Stein JH, Currier JS. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antivir Ther. 2017; 22(2):113-126. PMID: 27661466.
        View in: PubMed
      4. Dirajlal-Fargo S, Moser C, Brown TT, Kelesidis T, Dube M, Stein JH, Currier J, McComsey GA. Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s. Open Forum Infect Dis. 2016 Sep; 3(3):ofw174. PMID: 27704026.
        View in: PubMed
      5. Kelesidis T, Moser C, Stein JH, Brown TT, Tran TT, Ribaudo HJ, Dube M, Yang OO, Currier JS, McComsey GA. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. J Infect Dis. 2016 Sep 01; 214(5):748-52. PMID: 27354367; PMCID: PMC4978379 [Available on 09/01/17].
      6. Dan JM, Massanella M, Smith DM, Spina CA, Schrier R, Daar ES, Dube M, Morris SR, Gianella S. Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART. J Acquir Immune Defic Syndr. 2016 Jun 01; 72(2):133-7. PMID: 26818740; PMCID: PMC4868660.
      7. Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube M, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S. Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue. J Acquir Immune Defic Syndr. 2016 Jun 01; 72(2):e48-50. PMID: 26977746; PMCID: PMC4867124 [Available on 06/01/17].
      8. Gianella S, Ginocchio CC, Daar ES, Dube M, Morris SR. Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy. BMC Infect Dis. 2016 Jan 25; 16:24. PMID: 26809559; PMCID: PMC4727320.
      9. Vanpouille C, Introini A, Morris SR, Margolis L, Daar ES, Dube M, Little SJ, Smith DM, Lisco A, Gianella S. Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection. AIDS. 2016 Jan; 30(2):193-201. PMID: 26558730; PMCID: PMC4862605 [Available on 01/01/17].
      10. Stein JH, Ribaudo HJ, Hodis HN, Brown TT, Tran TT, Yan M, Brodell EL, Kelesidis T, McComsey GA, Dube M, Murphy RL, Currier JS. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015 Sep 10; 29(14):1775-83. PMID: 26372383; PMCID: PMC4571277.
      11. Massanella M, Gianella S, Schrier R, Dan JM, Pérez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson CA, Daar ES, Dube M, Haubrich RH, Smith DM, Morris SR. Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy. Sci Rep. 2015 Aug 24; 5:13179. PMID: 26299251; PMCID: PMC4547398.
      12. Gianella S, Smith DM, Daar ES, Dube M, Lisco A, Vanpouille C, Margolis L, Haubrich RH, Morris SR. Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men. PLoS One. 2015; 10(6):e0130410. PMID: 26061824; PMCID: PMC4465639.
      13. Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube M, Murphy R, Yang OO, Currier JS, McComsey GA. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin Infect Dis. 2015 Aug 15; 61(4):651-60. PMID: 25904376; PMCID: PMC4542595.
      14. Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube M, Haubrich RH, Morris SR, Smith DM. Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. J Virol. 2014 Jul; 88(14):7818-27. PMID: 24789781; PMCID: PMC4097769.
      15. Blumenthal J, Haubrich R, Jain S, Sun X, Dube M, Daar E, Milam J, Morris S. Factors associated with high transmission risk and detectable plasma HIV RNA in HIV-infected MSM on ART. Int J STD AIDS. 2014 Sep; 25(10):734-41. PMID: 24452730; PMCID: PMC4303352.
      16. Gianella S, Morris SR, Tatro E, Vargas MV, Haubrich RH, Daar ES, Dube M, Richman DD, Little SJ, Smith DM. Virologic correlates of anti-CMV IgG levels in HIV-1-infected men. J Infect Dis. 2014 Feb 01; 209(3):452-6. PMID: 23964106; PMCID: PMC3883163.
      17. Hulgan T, Stein JH, Cotter BR, Murdock DG, Ritchie MD, Dube M, Gerschenson M, Haas DW, Torriani FJ. Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses. 2013 Oct; 29(10):1293-9. PMID: 23944767; PMCID: PMC3785797.
      18. Grant PM, Kitch D, McComsey GA, Dube M, Haubrich R, Huang J, Riddler S, Tebas P, Zolopa AR, Collier AC, Brown TT. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis. 2013 Nov; 57(10):1483-8. PMID: 23943825; PMCID: PMC3805172.
      19. Gianella S, Smith DM, Vargas MV, Little SJ, Richman DD, Daar ES, Dube M, Zhang F, Ginocchio CC, Haubrich RH, Morris SR. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis. 2013 Aug; 57(3):441-7. PMID: 23595831; PMCID: PMC3703105.
      20. Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube M, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics J. 2014 Apr; 14(2):160-70. PMID: 23588107; PMCID: PMC4684079.
      21. Dubé MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab. 2011 Jun; 25(3):429-42. PMID: 21663837.
        View in: PubMed
      22. Dubé MP, Shen C, Mather KJ, Waltz J, Greenwald M, Gupta SK. Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. AIDS Res Hum Retroviruses. 2010 Aug; 26(8):847-54. PMID: 20673142; PMCID: PMC2957631.
      23. Murphy RL, Berzins B, Zala C, Fichtenbaum C, Dube M, Guaraldi G, Torriani F, Belsey E, Mitchell C, Stein JH. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS. 2010 Mar 27; 24(6):885-90. PMID: 19952712.
        View in: PubMed
      24. Ranade K, Geese WJ, Noor M, Flint O, Tebas P, Mulligan K, Powderly W, Grinspoon SK, Dube M. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008 Aug 20; 22(13):1561-8. PMID: 18670214; PMCID: PMC4410015.
      25. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K, Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar M, Tungsiripat M, Meyer W, Weihe J, Wanke C. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006 Sep 01; 43(5):645-53. PMID: 16886161.
        View in: PubMed
      26. Foulkes AS, Wohl DA, Frank I, Puleo E, Restine S, Wolfe ML, Dube M, Tebas P, Reilly MP. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006 Mar; 3(3):e52. PMID: 16417409; PMCID: PMC1334223.
      27. Henry K, Kitch D, Dube M, Zackin R, Parker RA, Sprecher D, Hammer S, Currier J. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS. 2004 Dec 03; 18(18):2434-7. PMID: 15622323.
        View in: PubMed
      28. Heiser CR, Ernst JA, Barrett JT, French N, Schutz M, Dube M. Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea. J Int Assoc Physicians AIDS Care (Chic). 2004 Oct-Dec; 3(4):121-9. PMID: 15768732.
        View in: PubMed
      29. Dube M, Fenton M. Lipid abnormalities. Clin Infect Dis. 2003 Apr 01; 36(Suppl 2):S79-83. PMID: 12652375.
        View in: PubMed
      30. Aberg JA, Williams PL, Liu T, Lederman HM, Hafner R, Torriani FJ, Lennox JL, Dube M, MacGregor RR, Currier JS. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. J Infect Dis. 2003 Apr 01; 187(7):1046-52. PMID: 12660918.
        View in: PubMed
      31. Sattler FR, Schroeder ET, Dube M, Jaque SV, Martinez C, Blanche PJ, Azen S, Krauss RM. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Am J Physiol Endocrinol Metab. 2002 Dec; 283(6):E1214-22. PMID: 12388173.
        View in: PubMed
      32. Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, Dube M. Elevated blood pressure in subjects with lipodystrophy. AIDS. 2001 Oct 19; 15(15):2001-10. PMID: 11600829.
        View in: PubMed
      33. Sattler FR, Jaque SV, Schroeder ET, Olson C, Dube M, Martinez C, Briggs W, Horton R, Azen S. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab. 1999 Apr; 84(4):1268-76. PMID: 10199766.
        View in: PubMed
      34. Dube M, Sattler FR. Metabolic complications of antiretroviral therapies. AIDS Clin Care. 1998 Jun; 10(6):41-4. PMID: 11365497.
        View in: PubMed
      35. Dib JC, Dube M, Kelly C, Rinaldi MG, Patterson JE. Evaluation of pulsed-field gel electrophoresis as a typing system for Candida rugosa: comparison of karyotype and restriction fragment length polymorphisms. J Clin Microbiol. 1996 Jun; 34(6):1494-6. PMID: 8735104; PMCID: PMC229048.
      36. Chaisson RE, Benson CA, Dube M, Heifets LB, Korvick JA, Elkin S, Smith T, Craft JC, Sattler FR. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994 Dec 15; 121(12):905-11. PMID: 7978715.
        View in: PubMed
      37. Dube M, Davis FB, Davis PJ, Schoenl M, Blas SD. Effects of hyperthyroidism and hypothyroidism on human red blood cell Ca2+-ATPase activity. J Clin Endocrinol Metab. 1986 Feb; 62(2):253-7. PMID: 2934403.
        View in: PubMed